Bo Huang
Research Subjects
Bo Huang has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
Alessandra di Pietro
Pfizer SRL, Milano, Italy
8 shared publications- Gaohong Dong
Stats Inc
7 shared publications - Bradley Alexander McGregor
Dana-Farber Cancer Institute 1 Lank Center for Genitourinary Oncology Boston, Massachusetts
6 shared publications - David C. Hoaglin
Department of Population and Quantitative Health Sciences UMass Chan Medical School Worcester Massachusetts USA
6 shared publications - Martin H. Voss
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
6 shared publications - Aly-Khan A. Lalani
Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
5 shared publications
Latest Publications
- 18 February 2026
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- p. 1-17
Win statistics (win ratio, win odds, and net benefit): Noncollapsibility and standardization for randomized clinical trials
The win ratio, along with its stratified variant known as the stratified win ratio, has been widely utilized in many disease areas for both design and analysis of clinical trials. It is applied most prominently in cardiovascular diseases, followed by respiratory disease, diabetes, oncology, neurology, and other areas. Additionally, the win odds, which incorporates ties in its calculation, has also garnered attention in both prospective and retrospective analyses, alongside their utilization in study design. Researchers have invested considerable effort in the statistical inference of the win statistics (win ratio, win odds, and net benefit). However, despite their significance, the issue of noncollapsibility, highlighted as critical in the FDA's covariate adjustment guidance in 2023, has not been thoroughly investigated for these win statistics. In this article, we investigate the noncollapsibility of win statistics in three typical types of clinical trial data: binary, continuous, and time-to-event data. We demonstrate that (1) the win ratio is noncollapsible for all of these three types of data; (2) both win odds and net benefit exhibit collapsibility for binary data but are noncollapsible for continuous and time-to-event data. Therefore, win statistics are generally noncollapsible. In light of these findings, we propose the use of stratified win statistics as a standardization approach for analyzing prioritized multiple outcomes, particularly in scenarios where noncollapsibility is a concern.
- 18 February 2026
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- p. 1-17
Win statistics (win ratio, win odds, and net benefit): Noncollapsibility and standardization for randomized clinical trials
The win ratio, along with its stratified variant known as the stratified win ratio, has been widely utilized in many disease areas for both design and analysis of clinical trials. It is applied most prominently in cardiovascular diseases, followed by respiratory disease, diabetes, oncology, neurology, and other areas. Additionally, the win odds, which incorporates ties in its calculation, has also garnered attention in both prospective and retrospective analyses, alongside their utilization in study design. Researchers have invested considerable effort in the statistical inference of the win statistics (win ratio, win odds, and net benefit). However, despite their significance, the issue of noncollapsibility, highlighted as critical in the FDA's covariate adjustment guidance in 2023, has not been thoroughly investigated for these win statistics. In this article, we investigate the noncollapsibility of win statistics in three typical types of clinical trial data: binary, continuous, and time-to-event data. We demonstrate that (1) the win ratio is noncollapsible for all of these three types of data; (2) both win odds and net benefit exhibit collapsibility for binary data but are noncollapsible for continuous and time-to-event data. Therefore, win statistics are generally noncollapsible. In light of these findings, we propose the use of stratified win statistics as a standardization approach for analyzing prioritized multiple outcomes, particularly in scenarios where noncollapsibility is a concern.
- 17 July 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (15-17) , e70180
An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties
In clinical trials, multiple outcomes of different priorities commonly occur as the patient's response may not be adequately characterized by a single outcome. Win statistics are appealing summary measures for between‐group difference at more than one endpoint. When defining the result of pairwise comparisons of a time‐to‐event endpoint, it is desirable to allow ties to account for incomplete follow‐up and not clinically meaningful difference in endpoints of interest. In this article, we propose a class of win statistics for time‐to‐event endpoints with a user‐specified equivalence margin. These win statistics are identifiable in the presence of right censoring and do not depend on the censoring distribution. We then develop estimation and inference procedures for the proposed win statistics based on inverse‐probability‐of‐censoring weighting adjustment to handle right censoring. We conduct extensive simulations to investigate the operational characteristics of the proposed procedure in the finite sample setting. A real oncology trial is used to illustrate the proposed approach.
- 17 July 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (15-17) , e70180
An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties
In clinical trials, multiple outcomes of different priorities commonly occur as the patient's response may not be adequately characterized by a single outcome. Win statistics are appealing summary measures for between‐group difference at more than one endpoint. When defining the result of pairwise comparisons of a time‐to‐event endpoint, it is desirable to allow ties to account for incomplete follow‐up and not clinically meaningful difference in endpoints of interest. In this article, we propose a class of win statistics for time‐to‐event endpoints with a user‐specified equivalence margin. These win statistics are identifiable in the presence of right censoring and do not depend on the censoring distribution. We then develop estimation and inference procedures for the proposed win statistics based on inverse‐probability‐of‐censoring weighting adjustment to handle right censoring. We conduct extensive simulations to investigate the operational characteristics of the proposed procedure in the finite sample setting. A real oncology trial is used to illustrate the proposed approach.
- 15 May 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (15) , 2972-2986
Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization
The U.S. Food and Drug Administration (FDA) has launched Project Optimus to shift dose selection from the maximum tolerated dose (MTD) to the dose that produces the optimal risk‐benefit tradeoff. One approach highlighted in the FDA's guidance involves conducting a randomized phase II trial following the completion of a phase I trial, where multiple doses (typically including the MTD and one or two doses lower than the MTD) are compared to identify the optimal dose that maximizes the benefit‐risk tradeoff. This article focuses on the design of such a multiple‐dose randomized trial, specifically the determination of the sample size. We generalized the standard definitions of type I error and power to accommodate the unique characteristics of dose optimization and derived a decision rule along with an algorithm to determine the optimal sample size. The resulting design is referred to as MERIT (Multiple‐dosE RandomIzed Trial design for dose optimization based on toxicity and efficacy). Simulation studies demonstrate that MERIT has desirable operating characteristics, and a sample size between 20 and 40 per dosage arm often offers reasonable power and type I errors to ensure patient safety and benefit. To facilitate the implementation of the MERIT design, we provide software, available at https://www.trialdesign.org.
- 15 May 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (15) , 2972-2986
Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization
The U.S. Food and Drug Administration (FDA) has launched Project Optimus to shift dose selection from the maximum tolerated dose (MTD) to the dose that produces the optimal risk‐benefit tradeoff. One approach highlighted in the FDA's guidance involves conducting a randomized phase II trial following the completion of a phase I trial, where multiple doses (typically including the MTD and one or two doses lower than the MTD) are compared to identify the optimal dose that maximizes the benefit‐risk tradeoff. This article focuses on the design of such a multiple‐dose randomized trial, specifically the determination of the sample size. We generalized the standard definitions of type I error and power to accommodate the unique characteristics of dose optimization and derived a decision rule along with an algorithm to determine the optimal sample size. The resulting design is referred to as MERIT (Multiple‐dosE RandomIzed Trial design for dose optimization based on toxicity and efficacy). Simulation studies demonstrate that MERIT has desirable operating characteristics, and a sample size between 20 and 40 per dosage arm often offers reasonable power and type I errors to ensure patient safety and benefit. To facilitate the implementation of the MERIT design, we provide software, available at https://www.trialdesign.org.
- 26 February 2024
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 16 (3) , 326-337
Dose Optimization for Novel Oncology Agents: Design Options and Strategies
- 26 February 2024
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 16 (3) , 326-337
Dose Optimization for Novel Oncology Agents: Design Options and Strategies
- 27 November 2023
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 17 (1) , 17-26
Nonconcurrent Controls in Platform Trials: Can We Borrow Their Concurrent Observation Data?
- 27 November 2023
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 17 (1) , 17-26
Nonconcurrent Controls in Platform Trials: Can We Borrow Their Concurrent Observation Data?
- 10 November 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 35 (1) , 21-36
Adjusted win ratio using the inverse probability of treatment weighting
The win ratio method has been increasingly applied in the design and analysis of clinical trials. However, the win ratio method is a univariate approach that does not allow for adjusting for baseline imbalances in covariates, although a stratified win ratio can be calculated when the number of strata is small. This paper proposes an adjusted win ratio to control for such imbalances by inverse probability of treatment weighting (IPTW) method. We derive the adjusted win ratio with its variance and suggest three IPTW adjustments: IPTW-average treatment effect (IPTW-ATE), stabilized IPTW-ATE (SIPTW-ATE) and IPTW-average treatment effect in the treated (IPTW-ATT). The proposed adjusted methods are applied to analyse a composite outcome in the CHARM trial. The statistical properties of the methods are assessed through simulations. Results show that adjusted win ratio methods can correct the win ratio for covariate imbalances at baseline. Simulation results show that the three proposed adjusted win ratios have similar power to detect the treatment difference and have slightly lower power than the corresponding adjusted Cox models when the assumption of proportional hazards holds true but have consistently higher power than adjusted Cox models when the proportional hazard assumption is violated.
- 10 November 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 35 (1) , 21-36
Adjusted win ratio using the inverse probability of treatment weighting
The win ratio method has been increasingly applied in the design and analysis of clinical trials. However, the win ratio method is a univariate approach that does not allow for adjusting for baseline imbalances in covariates, although a stratified win ratio can be calculated when the number of strata is small. This paper proposes an adjusted win ratio to control for such imbalances by inverse probability of treatment weighting (IPTW) method. We derive the adjusted win ratio with its variance and suggest three IPTW adjustments: IPTW-average treatment effect (IPTW-ATE), stabilized IPTW-ATE (SIPTW-ATE) and IPTW-average treatment effect in the treated (IPTW-ATT). The proposed adjusted methods are applied to analyse a composite outcome in the CHARM trial. The statistical properties of the methods are assessed through simulations. Results show that adjusted win ratio methods can correct the win ratio for covariate imbalances at baseline. Simulation results show that the three proposed adjusted win ratios have similar power to detect the treatment difference and have slightly lower power than the corresponding adjusted Cox models when the assumption of proportional hazards holds true but have consistently higher power than adjusted Cox models when the proportional hazard assumption is violated.
- Top Cited PapersOpen Access
- 1 July 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (19) , 3486-3492
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Initial results from the phase III JAVELIN Bladder 100 trial (ClinicalTrials.gov identifier: NCT02603432 ) showed that avelumab first-line (1L) maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) who were progression-free after 1L platinum-containing chemotherapy. Avelumab 1L maintenance treatment is now a standard of care for aUC. Here, we report updated data with ≥ 2 years of follow-up in all patients, including OS (primary end point), PFS, safety, and additional novel analyses. Patients were randomly assigned 1:1 to receive avelumab plus BSC (n = 350) or BSC alone (n = 350). At data cutoff (June 4, 2021), median follow-up was 38.0 months and 39.6 months, respectively; 67 patients (19.5%) had received ≥2 years of avelumab treatment. OS remained longer with avelumab plus BSC versus BSC alone in all patients (hazard ratio, 0.76 [95% CI, 0.63 to 0.91]; 2-sided P = .0036). Investigator-assessed PFS analyses also favored avelumab. Longer-term safety was consistent with previous analyses; no new safety signals were identified with longer treatment duration. In conclusion, longer-term follow-up continues to show clinically meaningful efficacy benefits with avelumab 1L maintenance plus BSC versus BSC alone in patients with aUC. An interactive visualization of data reported in this article is available.
- 1 July 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (19) , 3486-3492
Top Cited PapersOpen AccessAvelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Initial results from the phase III JAVELIN Bladder 100 trial (ClinicalTrials.gov identifier: NCT02603432 ) showed that avelumab first-line (1L) maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) who were progression-free after 1L platinum-containing chemotherapy. Avelumab 1L maintenance treatment is now a standard of care for aUC. Here, we report updated data with ≥ 2 years of follow-up in all patients, including OS (primary end point), PFS, safety, and additional novel analyses. Patients were randomly assigned 1:1 to receive avelumab plus BSC (n = 350) or BSC alone (n = 350). At data cutoff (June 4, 2021), median follow-up was 38.0 months and 39.6 months, respectively; 67 patients (19.5%) had received ≥2 years of avelumab treatment. OS remained longer with avelumab plus BSC versus BSC alone in all patients (hazard ratio, 0.76 [95% CI, 0.63 to 0.91]; 2-sided P = .0036). Investigator-assessed PFS analyses also favored avelumab. Longer-term safety was consistent with previous analyses; no new safety signals were identified with longer treatment duration. In conclusion, longer-term follow-up continues to show clinically meaningful efficacy benefits with avelumab 1L maintenance plus BSC versus BSC alone in patients with aUC. An interactive visualization of data reported in this article is available.